Novo Nordisk President and Global CEO Sovetson announced on November 11 that it will build a new largest insulin preparation and filling plant in Tianjin.
The new plant invested a total of 381 million U.S. dollars, which is Novo Nordisk's largest single investment so far, and it is also the largest single investment in improving the production of insulin and filling. On the same day, the groundbreaking ceremony for the new factory was held in Tianjin TEDA Development Zone and is expected to be fully operational in 2012. The newly built factory will become Novo Nordisk's primary production base in the Asia-Pacific region, providing insulin "special injection" injection devices and insulin refill products for domestic and global markets, Novorush 30, Novozymes, and long-acting insulin. Levemir et al. also plan to fill production at the new plant.
In the context of the global financial crisis, Novo Nordisk’s large-scale investment is particularly eye-catching. "The new plant in Tianjin will become the world's most advanced insulin preparation and filling plant, which highlights the importance of China in Novo Nordisk's global business," said Sovenson.
China is the world’s second largest diabetes nation after India. Nearly 40 million people in the country suffer from diabetes. The ageing of the population, the excessive intake of high-fat foods, and the lack of a sporty lifestyle all mean that this issue may be further developed. One obvious sign is that about 64 million Chinese have impaired glucose tolerance or have prediabetes. The huge market in China and the Asia-Pacific region is an important reason for attracting Nordisk Nord to further increase investment.
The new plant invested a total of 381 million U.S. dollars, which is Novo Nordisk's largest single investment so far, and it is also the largest single investment in improving the production of insulin and filling. On the same day, the groundbreaking ceremony for the new factory was held in Tianjin TEDA Development Zone and is expected to be fully operational in 2012. The newly built factory will become Novo Nordisk's primary production base in the Asia-Pacific region, providing insulin "special injection" injection devices and insulin refill products for domestic and global markets, Novorush 30, Novozymes, and long-acting insulin. Levemir et al. also plan to fill production at the new plant.
In the context of the global financial crisis, Novo Nordisk’s large-scale investment is particularly eye-catching. "The new plant in Tianjin will become the world's most advanced insulin preparation and filling plant, which highlights the importance of China in Novo Nordisk's global business," said Sovenson.
China is the world’s second largest diabetes nation after India. Nearly 40 million people in the country suffer from diabetes. The ageing of the population, the excessive intake of high-fat foods, and the lack of a sporty lifestyle all mean that this issue may be further developed. One obvious sign is that about 64 million Chinese have impaired glucose tolerance or have prediabetes. The huge market in China and the Asia-Pacific region is an important reason for attracting Nordisk Nord to further increase investment.
Hubei ruiyate Automobile Co.,Ltd , https://www.nbruiyate-automobile.com